Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tenapanor

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 08, 2020


            Tenapanor’s effect of decreasing pill burden of phosphate binders , which is the outcome of a phase 2 study of tenapanor for hemodialysis patients with hyperphosphatemia in Japan, was presented in a poster session virtually at ERA-EDTA 2020 Anual Meeting.